#	Pagina
attuale pagina	/open-h2020/projects/219121/index.html
-1	/open-ted/ita/index.html

Opendata, web and dolomites

RESHAPE SIGNED

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

RESHAPE project word cloud

Explore the words cloud of the RESHAPE project. It provides you a very rough idea of what is the project "RESHAPE" about.

transform encouraging pioneers broad immune diseases entities limited basic regulatory generation host allografts cas9 rejection science disease biotech overcoming gene biomarker supports proven regenerative record medicinal graft presently recipient translation longtrack stability ec adoptive platforms hsc economic options enhanced overcome antigen specificity health academic changer inflammation members versus atmp patients vivo accompanied cell reshape triple preclinical conditioning transplant technologies data stem first reaction transdisciplinarity game allotransplantation limitations imbalance curative fih option medicine transfer treatment cells function models crispr suffering hematopoietic transplantation tested therapy tissue trials vitro studies performed clinical human immunity backgrounds 1st therapeutic undesired organ treg functional combat care

Project "RESHAPE" data sheet

The following table provides information about the project.

Coordinator	CHARITE - UNIVERSITAETSMEDIZIN BERLIN Organization address address: Chariteplatz 1 city: BERLIN postcode: 10117 website: www.charite.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Total cost	13˙137˙396 €
EC max contribution	13˙137˙396 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2018-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2022-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CHARITE - UNIVERSITAETSMEDIZIN BERLIN CHARITE - UNIVERSITAETSMEDIZIN BERLIN Organization address address: Chariteplatz 1 city: BERLIN postcode: 10117 website: www.charite.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	coordinator	4˙137˙775.00
2	CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES Organization address address: Allee de l'Ile Gloriette 5 city: NANTES postcode: 44093 website: www.chu-nantes.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (NANTES)	participant	2˙023˙468.00
3	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	participant	1˙998˙550.00
4	MEDIZINISCHE HOCHSCHULE HANNOVER MEDIZINISCHE HOCHSCHULE HANNOVER Organization address address: Carl-Neuberg-Strasse 1 city: HANNOVER postcode: 30625 website: www.mh-hannover.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HANNOVER)	participant	1˙548˙050.00
5	TISSUSE GMBH TISSUSE GMBH Organization address address: OUDENARDER STRASSE 16 city: BERLIN postcode: 13347 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	participant	1˙026˙250.00
6	CELL THERAPY CATAPULT LIMITED CELL THERAPY CATAPULT LIMITED Organization address address: 12TH FLOOR TOWER WING GUY'S HOSPITAL GREAT MAZE POND city: LONDON postcode: SE1 9RT website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	975˙625.00
7	TXCELL TXCELL Organization address address: LES CARDOULINES ALLEE DE LA NERTIERE SOPHIA ANTIPOLIS city: VALBONNE postcode: 6560 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (VALBONNE)	participant	502˙077.00
8	NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN Organization address address: MARKWIESENSTRASSE 55 city: REUTLINGEN postcode: 72770 website: www.nmi.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (REUTLINGEN)	participant	499˙500.00
9	INNOVATION ACTA S.R.L. INNOVATION ACTA S.R.L. Organization address address: VIA D.A. AZUNI, 9 city: ROMA postcode: 196 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	participant	426˙100.00

Map

Project objective

Adoptive transfer of regulatory T cells (Treg) is a promising new therapeutic option to reshape undesired intra-tissue immune imbalance in immune-related disease entities. It supports long-term function of allografts and use of Advanced Therapy Medicinal Products (ATMP) by overcoming the challenge of unwanted immune reaction by the recipient of the ATMP. Therefore, adoptive Treg therapy is a potential game changer in health care, particularly in immune diseases, organ & hematopoietic stem cell (HSC) transplantation, and regenerative medicine, including gene therapy. Based on the Triple-T concept - Transdisciplinarity, Technology, Translation - the major goal of RESHAPE is to transform the treatment of patients suffering from undesired immunity/inflammation, who presently have limited curative treatment options, by applying novel Treg approaches that overcome the limitations of 1st generation Treg product developments. Members of the consortium, with academic & biotech backgrounds, are pioneers in the development of Treg therapy from basic science to very recent encouraging First-In-Human (FIH) clinical trials of the 1st generation Treg products. They have a longtrack record of collaboration, including in EC-funded projects. The first clinical trials were performed to combat organ transplant rejection and Graft-versus-Host-Disease. However, promising preclinical studies offer a broad application field of Treg therapy beyond allotransplantation. Based on our preclinical & clinical data, we have identified several opportunities for improving Treg therapy, such as enhanced antigen specificity & functional stability, and recipient conditioning, that will be addressed by RESHAPE. The next-generation Treg products, developed by advanced technologies including CRISPR/Cas9, will be tested on platforms applying new methods for cell characteristics in both in vivo /in vitro models, and finally proven in FIH-clinical trials accompanied by biomarker and health economic studies

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESHAPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESHAPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More